Dermata Therapeutics Stock Target Price and Analyst Consensus
| DRMA Stock | USD 2.80 0.28 11.11% |
The current analyst and expert consensus on Dermata Therapeutics is Buy, with no strong buy opinions. The current projected Dermata Therapeutics target price consensus is 10.00 with 1 analyst opinions. Check out Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.The most common way Dermata Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Dermata Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Dermata Therapeutics. We encourage you to use your own analysis of Dermata Therapeutics to validate this buy or sell advice. Dermata Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Dermata Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 5.7673.
Lowest Forecast 9.1 | Highest Forecast 11.1 | Target Price 10 |
It's important to approach Dermata Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Dermata Therapeutics Target Price Consensus
Dermata target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dermata Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Dermata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dermata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dermata Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDermata Therapeutics Target Price Projection
Dermata Therapeutics' current and average target prices are 2.80 and 10.00, respectively. The current price of Dermata Therapeutics is the price at which Dermata Therapeutics is currently trading. On the other hand, Dermata Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dermata Therapeutics Market Quote on 5th of December 2025
Target Price
Analyst Consensus On Dermata Therapeutics Target Price
Dermata Therapeutics Analyst Ratings
Dermata Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Dermata Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Dermata Therapeutics' financials, market performance, and future outlook by experienced professionals. Dermata Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Dermata Therapeutics price targets
Dermata Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Dermata Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Dermata Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Dermata Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Dermata Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Dermata Therapeutics is a key component of Dermata Therapeutics valuation and have some predictive power on the future returns of a Dermata Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Adviser Favorites Invested few shares | |
 | Momentum Invested over 30 shares | |
 | Advertising Invested few shares | |
 | Dividend Beast Invested over 40 shares | |
 | Warren Buffett Holdings Invested over 50 shares | |
 | Impulse Invested over 100 shares | |
 | Marketing Invested few shares | |
 | Investor Favorites Invested over 200 shares | |
 | Macroaxis Index Invested over 40 shares | |
 | Manufacturing Invested over 70 shares | |
 | Artificial Intelligence Invested over 90 shares |
Check out Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Please note, the presentation of Dermata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dermata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dermata Therapeutics' management manipulating its earnings.